Drug Profile
MVT 2163
Alternative Names: 89Zr-DFO-HuMab-5B1; 89Zr-HuMab 5B1; MVT-2163; PET Imaging agent - MabVax Therapeutics; Radiolabelled 5B1 diabody (sLeA); Zirconium anti-sialyl Lewisa imaging agent - MabVaxLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator HonorHealth; MabVax Therapeutics
- Developer BioNTech; MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class Drug conjugates; Imaging agents; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Diagnostic imaging enhancers; Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pancreatic cancer
- No development reported Bladder cancer; Colorectal cancer; Small cell lung cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Bladder-cancer(Diagnosis) in USA (Parenteral)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Colorectal-cancer(Diagnosis) in USA (Parenteral)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Diagnosis) in USA (Parenteral)